Centella asiatica / gotu kola improves venous hypertension / water retention, placebo-controlled clinical study reports

  • Venous hypertension occurs when the return of blood from the lower legs towards the heart is inhibited, due to poor vein function, resulting in water retention as well as vein damage.
  • In a study which examined the effect of what is called the Total Triterpenic Fraction of Centella Asiatica (TTFCA) it was found that TTFCA does significantly improve vein function and veneers hypertension in just 8 weeks, resulting in objective improvement (better leg tissue oxygenation, better removal of carbon dioxide from tissues, improved overall circulation, reduced ankle swelling); and subjective improvement (feeling of heaviness, itching, pain, puffiness etc.) as reported by patients. The study showed that the higher dose of centella asiatica (120mg of TTFCA per day) offered the most impressive results. The placebo group experienced no results at all.
  • This is one of multiple studies about the effect of centella asiatica on circulation and vein health improvement. Centella asiatica (gotu kola) is widely used in Europe for water retention and skin firming, both as a nutritional supplement as well as an active ingredient in anti-cellulite / leg wellness creams. For cellulite / leg wellness creams, the best form of centella asiatica is one comprising 90-100% of any (or all) of the four important active molecules found in centella: pure asiatic acid, madecassic acid, madecassoside and asiaticoside, as used in this study. Creams can contain centella extracts with as little as 0.1% of those active molecules, so doing your research before choosing an anti-cellulite cream is essential
  • Source: Total triterpenic fraction of Centella asiatica in the treatment of venous hypertension: a clinical, prospective, randomized trial using a combined microcirculatory model
  • Abstract: A single-blind, placebo-controlled, randomized study was performed on the effects of different doses of the total triterpenic fraction of Centella asiatica (TTFCA) in patients with venous hypertensive microangiopathy. A combined microcirculatory model that considers laser Doppler flowmetry (LDF) and transcutaneous oxygen (PO2), transcutaneous carbon dioxide tension (PCO2) measurements was combined with the symptom evaluation. LDF tests included the baseline resting flow, the venoarteriolar reflex, and the variation of flow related to the temperature increase. All tests provided a significant difference between drug-treated groups and the placebo group, thereby allowing a distinction to be made between the higher (120 mg daily) and the lower (60 mg daily) dose of TTFCA. Transcutaneous PO2-PCO2 measurements were significantly modified by drug treatments, while no variation could be detected in the placebo group. Important symptomatologic effects (evaluated by subjective scores) followed TTFCA administration, especially at the higher dose level, while no effect was obtained with placebo. The trend of symptom evaluation paralleled the results of objective tests of our microcirculatory model, providing evidence that this model can reveal effects of venoactive drugs on venous hypertensive microangiopathy. TTFCA displays a significant activity. Doses as high as 120 mg daily may be safely used in venous hypertension.
  • Source 2: Effects of the total triterpenic fraction of Centella asiatica in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial.
  • Abstract 2: The aim of this study was to demonstrate whether total triterpenic fraction of Centella asiatica (TTFCA), was effective in improving the microcirculation in venous hypertension and microangiopathy. Forty patients with severe venous hypertension, ankle swelling, lipodermatosclerosis were included. After informed consent, patients were randomized into a treatment and a placebo group: those in the treatment group received TTFCA (tablets, 60 mg, twice daily for 8 weeks). The two groups of subjects were comparable for age and sex distribution. The mean age was 48 years (SD 9; M:F= 11:11) in the treatment group (22 patients) and 47.6 (SD 7; M:F= 10:8) in the placebo group (18 patients). There were no differences between placebo and treatment group at inclusion; there was no change between inclusion and measurements at 8 weeks in the placebo group. A decrease (p < 0.05) in RF (flux at rest) and RAS (rate of ankle swelling) were observed in the treatment group. The decrease in capillary filtration was associated with improvement in signs and symptoms (p < 0.05). The difference in flux, signs and symptoms, and filtration was clinically important at 8 weeks. No side effects were observed. In conclusion venous microangiopathy was improved by TTFCA treatment.

< Back to centella asiatica / gotu kola